Drug Trial Radar · NCT04764474
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
46
Actual
Start
Apr 12, 2021
Primary completion
Jan 15, 2025
Study completion Jan 15, 2025
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Conditions
- Isocitrate Dehydrogenase Gene Mutation
Interventions
HMPL-306Drug
Administered orally QD in a 28-day continuous dosing treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
- Dose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs)Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
- Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
Orange, California
Winship Cancer Institute - Emory University
Atlanta, Georgia
University of Massachusetts Medical School
Worcester, Massachusetts
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
The University of Texas MD Anderson Cancer Center
Houston, Texas
Froedtert-Medical College of WI
Milwaukee, Wisconsin
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Institut Catala d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals
Barcelona, Spain
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Hospital Clinico Universitario de Valencia
Valencia, Valencia, Spain
Hospital Universitario La Fe
Valencia, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.